Compass Therapeutics, Inc. (CMPX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.38+0.42%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CMPX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 742.4% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
CMPX — earnings miss
Dated 2026-08-06
104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Compass Therapeutics, Inc. Date: August 6, 2026 By: /s/ Neil Lerner Neil Lerner Chief Accounting Officer
Why it matters: A drop in cash reserves could indicate financial strain. This may impact the company's ability to fund operations.
Worry ifCash and marketable securities are less than $180 million.
Less concerning ifCash and marketable securities are more than $180 million. This shows stable funding.
Why it matters: Feedback from the FDA could impact the timing of the BLA filing for tovecimig. This drug is crucial for patients with biliary tract cancer.
Supportive ifThe FDA gives good feedback on the tovecimig Phase 2/3 data before Q3 2026.
Worry ifThe FDA gives bad feedback or shows big concerns about the data.
Why it matters: If the healthcare sector grows faster, it may help Compass's performance.
Supportive ifHealthcare sector revenue growth speeds up above 10% each year.
Worry ifHealthcare sector revenue growth keeps slowing down below 9% each year.
Why it matters: Watching cash burn will show if the company can keep running until 2028.
Worry ifCash burn remains stable or decreases in Q2 2026 results.
Less concerning ifCash burn goes up a lot in Q2 2026 results.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$250 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $617 loss on $10,000 · 6.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,504 loss on $10,000 · 75.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Larger losses may mean bigger financial problems and hurt investor trust.
Worry ifOperating losses in Q2 2026 exceed -$20.3M reported in Q1 2026.
Less concerning ifOperating losses get better or stay the same compared to Q1 2026.
Why it matters: Starting the Phase 2 trial for CTX-471 shows progress in the pipeline and could attract investor interest.
Supportive ifCTX-471 Phase 2 trial is initiated in Q3 2026 as planned.
Worry ifThe initiation of the CTX-471 Phase 2 trial is delayed or canceled.
Why it matters: Updates on cash reserves will show if Compass can keep running until 2028. A big drop could worry investors about finances.
Worry ifCash and marketable securities are more than $180 million in Q3.
Less concerning ifCash and marketable securities are less than $180 million in Q3.
Why it matters: Results will show how well the company is doing in clinical development. This will affect future growth.
Supportive ifManagement says the results from secondary endpoints in Q1 2026 are good.
Worry ifResults from secondary endpoints are not good or are late.
Why it matters: This meeting is key for the future approval of tovecimig for biliary tract cancer. A successful meeting could lead to a faster market entry.
Supportive ifConfirmation of the FDA meeting scheduled for Q3 2026.
Worry ifNo meeting occurs or is delayed beyond Q3 2026.
Why it matters: Updates on CTX-8371 may show the drug's potential after checkpoint inhibitors. Good results may raise the pipeline's value.
Watch forData from CTX-8371 cohort expansions shows strong and lasting results.
Also watch forData from CTX-8371 cohort expansions shows weak or no results.
Why it matters: Updates on cash sufficiency show if the company can run without more money.
Supportive ifManagement says there is enough cash to run operations until 2028 without new funds.
Worry ifManagement says more funding is needed or cash may run low before 2028.
Why it matters: The earnings report will show how the company is doing financially. It will also share plans for the future.
Watch forA good earnings date announcement. It includes positive news about revenue or pipeline progress.
Also watch forNo earnings date announcement or bad news on revenue or pipeline.
Why it matters: Data from this presentation will show how well CTX-8371 works after checkpoint inhibitors.
Supportive ifData from CTX-8371 is presented at ASCO 2026.
Worry ifNo presentation occurs or data is not shared at ASCO 2026.
Why it matters: A bigger loss could mean more cash burn and problems. This may worry investors.
Worry ifQ3 operating loss is over $25 million.
Less concerning ifThe company lost less than $25 million. This shows better control of costs.
Why it matters: Initial data from this study could show the drug's potential in treating solid tumors. Positive results may boost investor confidence.
Supportive ifEarly clinical data from the CTX-10726 study shows good results in Q4 2026.
Worry ifEarly data shows no good results or safety issues that stop the study.